Sponsored Links

BRIEF-Celldex Therapeutics up in premarket after CDX-011 phase 2 study results

NEW YORK | Mon Dec 10, 2012 8:55am EST

NEW YORK Dec 10 (Reuters) - Celldex Therapeutics Inc : * Up 9.6 percent to $6.05 in premarket after CDX-011 phase 2 study results in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer
Stocks
Markets
Healthcare
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.